563 related articles for article (PubMed ID: 26660725)
1. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
3. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Dalrymple SL; Becker RE; Isaacs JT
Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
[TBL] [Abstract][Full Text] [Related]
4. [Tasquinimod: How to act on microenvironment in metastatic prostate cancer].
Houédé N; Irani J
Prog Urol; 2015 May; 25(6):298-305. PubMed ID: 25684391
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of CRMP4, a new prostate cancer metastasis suppressor gene, inhibits tumor growth in a nude mouse intratibial injection model.
Zhou W; Xie P; Pang M; Yang B; Fang Y; Shu T; Liu C; Wang X; Zhang L; Li S; Rong L
Int J Oncol; 2015 Jan; 46(1):290-8. PubMed ID: 25338524
[TBL] [Abstract][Full Text] [Related]
6. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Isaacs JT; Dalrymple SL; Rosen DM; Hammers H; Olsson A; Leanderson T
Oncotarget; 2014 Sep; 5(18):8093-106. PubMed ID: 25193858
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth.
Deronic A; Tahvili S; Leanderson T; Ivars F
BMC Cancer; 2016 Jul; 16():440. PubMed ID: 27400708
[TBL] [Abstract][Full Text] [Related]
8. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
Armstrong AJ; Häggman M; Stadler WM; Gingrich JR; Assikis V; Polikoff J; Damber JE; Belkoff L; Nordle Ö; Forsberg G; Carducci MA; Pili R
Clin Cancer Res; 2013 Dec; 19(24):6891-901. PubMed ID: 24255071
[TBL] [Abstract][Full Text] [Related]
10. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.
Hagberg Thulin M; Jennbacken K; Damber JE; Welén K
Clin Exp Metastasis; 2014 Mar; 31(3):269-83. PubMed ID: 24292404
[TBL] [Abstract][Full Text] [Related]
11. Tasquinimod: a novel drug in advanced prostate cancer.
Osanto S; van Poppel H; Burggraaf J
Future Oncol; 2013 Sep; 9(9):1271-81. PubMed ID: 23980674
[TBL] [Abstract][Full Text] [Related]
12. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
13. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.
Shen L; Sundstedt A; Ciesielski M; Miles KM; Celander M; Adelaiye R; Orillion A; Ciamporcero E; Ramakrishnan S; Ellis L; Fenstermaker R; Abrams SI; Eriksson H; Leanderson T; Olsson A; Pili R
Cancer Immunol Res; 2015 Feb; 3(2):136-48. PubMed ID: 25370534
[TBL] [Abstract][Full Text] [Related]
14. Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment.
Kolb AD; Shupp AB; Mukhopadhyay D; Marini FC; Bussard KM
Breast Cancer Res; 2019 Feb; 21(1):31. PubMed ID: 30813947
[TBL] [Abstract][Full Text] [Related]
15. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA
J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011
[TBL] [Abstract][Full Text] [Related]
16. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
Nordstrand A; Bergström SH; Thysell E; Bovinder-Ylitalo E; Lerner UH; Widmark A; Bergh A; Wikström P
Clin Exp Metastasis; 2017 Apr; 34(3-4):261-271. PubMed ID: 28447314
[TBL] [Abstract][Full Text] [Related]
18. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
19. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
[TBL] [Abstract][Full Text] [Related]
20. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.
Xu S; Zhang Z; Ogawa O; Yoshikawa T; Sakamoto H; Shibasaki N; Goto T; Wang L; Terada N
Cell Biochem Biophys; 2014 Sep; 70(1):521-7. PubMed ID: 24744183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
